The firm, which markets a clinical immunosequencing assay for leukemia and multiple myeloma, had originally expected to sell its shares at $15 to $17 apiece.
Adaptive currently offers a clinical immunosequencing assay for monitoring minimal residual disease in multiple myeloma and acute lymphoblastic leukemia.
The firm plans to use proceeds to fund commercial activities related to its ClonoSeq assay, as well as research into drug discovery and its project to map TCR antigens.
The expected gross proceeds are more than double what the firm proposed as its original goal for the offering when it filed plans to list its shares in September.
The newly independent firm will continue to invest in diagnostics by bringing its menu of PCR tests for infectious diseases to the US and other markets, among other objectives.
The listing will allow Siemens Healthineers to invest in high-growth health sectors, such as molecular diagnostics, and to acquire US-based healthcare technology startups.
Siemens disclosed its plans for the IPO last month. It said on Monday that as an independent company, Siemens Healthineers will have greater entrepreneurial flexibility.
The company recorded €13.8 billion in revenues in fiscal 2017, including €4.2 billion in diagnostics, €8.2 billion in imaging, and €1.5 billion in advanced therapies.
